Lantheus Gains Tentative FDA Approval for PNT2003 as First Radioequivalent for Lu 177 Dotatate

The FDA's tentative approval of Lantheus's PNT2003 as the first radioequivalent for Lutetium Lu 177 Dotatate signals that radiopharmaceutical generics are no longer a theoretical regulatory category, and plant heads and QA directors eyeing this space now have a concrete manufacturing and compliance benchmark to work against. The designation, disclosed alongside Lantheus's first quarter 2026 results, positions PNT2003 as the reference point for GMP facility requirements, short shelf-life logistics, and the emerging radioequivalent pathway under 21 CFR frameworks.

Radiopharmaceutical generics carry manufacturing constraints that standard small-molecule generic pathways do not. Decay-sensitive shelf lives compress release testing windows, hot-cell infrastructure demands differ materially from conventional sterile fill-finish, and sterility assurance protocols must account for the impossibility of terminal sterilization in many isotope-based products. For contract manufacturers evaluating entry into this space, PNT2003's tentative approval provides the first real-world regulatory data point on what an acceptable radioequivalent dossier looks like for a peptide receptor radionuclide therapy.

Lantheus also reported FDA approval for PYLARIFY TruVu (piflufolastat F18) during the quarter, with a phased geographic launch planned to begin in Q4 2026. The company described the rollout as a conversion from the existing PYLARIFY franchise, a sequencing decision with direct implications for radiopharmacy network planning and site qualification timelines at imaging centers currently operating under the legacy product's procedures.

On the financial side, worldwide revenue reached $377.3 million for the quarter ended March 31, 2026, a 1.2% increase year-over-year. PYLARIFY sales of $240.9 million represented a 6.5% decline, while DEFINITY grew 6.8% to $84.6 million. Adjusted fully diluted earnings per share came in at $1.46, down from $1.53 in the prior-year period, reflecting increased operating investment. Cash and cash equivalents stood at $498.6 million at quarter-end, providing capacity for the capital deployment the company flagged toward radiodiagnostics priorities.

The measurable near-term checkpoint for operations and regulatory teams is the Q4 2026 PYLARIFY TruVu launch conversion, which will test site readiness, updated process validation documentation, and supply-chain continuity across Lantheus's radiopharmacy distribution network simultaneously with the broader industry's first close read of the radioequivalent approval framework PNT2003 has now established.

Source: Lantheus Holdings, Inc. via GlobeNewswire, May 7, 2026.